• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Current opinion in gastroenterology >Gastric acidity inhibitors and the risk of intestinal infections.
【24h】

Gastric acidity inhibitors and the risk of intestinal infections.

机译：胃酸抑制剂和肠道感染的风险。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

PURPOSE OF REVIEW: We reviewed recent clinical studies performed in adults, children, and neonates exploring the possible association of gastric acidity inhibitors use with intestinal infections. Possible mechanisms have also been reported. RECENT FINDINGS: Many studies and systematic reviews demonstrate an increased risk of bacterial infection in adults taking acid suppressors. Little evidence is derived from the pediatric population. The use of gastric acidity inhibitors has been associated with systemic infections and necrotizing enterocolitis in preterm infants. Reduced gastric acidity, delayed gastric emptying, increased gastric mucus viscosity, modification in microbiota, and impairment of neutrophils functions, are all conditions determined by gastric acidity blockers that potentially lead to an increased risk of gastrointestinal infections. SUMMARY: A proper utilization of these drugs, particularly for patients at high risk, is imperative in order to reduce deleterious effects on infection risk and to optimize cost-effectiveness ratio.
机译：审查的目的：我们审查了最近在成人，儿童和新生儿中进行的临床研究，探讨了胃酸抑制剂与肠道感染的可能联系。也已经报道了可能的机制。最近的发现：许多研究和系统评价表明，服用抑酸剂的成年人细菌感染的风险增加。很少证据来自儿科人群。早产儿使用胃酸抑制剂与全身感染和坏死性小肠结肠炎有关。胃酸阻滞剂决定了胃酸度降低，胃排空延迟，胃粘液黏度增加，微生物群改变以及中性粒细胞功能受损，这些条件均可能导致胃酸感染的风险增加。简介：为了减少对感染风险的有害影响并优化成本效益比，必须正确使用这些药物，尤其是对高危患者尤其如此。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号